Domain Partners β Full Portfolio
7 tracked investments Β· listed companies and verified rows first
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Board seatJames C. BlairΒ· per SEC Form D Β· $76.3M raise Β· filed Apr 2015
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesDomain AssociatesPolaris PartnersSamsara BioCapital+1 more
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US
Paul Flook(Executive Officer, Director)inGregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)inAxel Scherer(Director)
BoardJustin Klein(Director)in
Board seatJames C. BlairΒ· per SEC Form D Β· $12.1M raise Β· filed Apr 2017
Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Associates+2 more
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.
BiotechHealthtechLa Jolla, US
Preston Klassen(Executive Officer)inJoseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)
BoardEckard Weber(Director)
Board seatBrian H. DoveyΒ· per SEC Form D Β· $49.6M raise Β· filed Mar 2017
Co-investorsCross Creek AdvisorsNew Enterprise Associates (NEA)Sofinnova VenturesDomain Associates
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDelos Capital+8 more
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.